Correction: High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients (PLoS ONE (2017) 12:5 (e0176984) DOI: 10.1371/journal.pone.0176984);High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Honda, Hirokazu ^a   Michihata, Tetsuo ^b   Shishido, Kanji ^c   Takahashi, Keiko ^d   Takahashi, Go ^a   Hosaka, Nozomu ^a   Ikeda, Misa ^a   Sanada, Daisuke ^a   Shibata, Takanori ^a  

^a SHOWA UNIVERSITY   (Japan)

^b Department of Dialysis   (Japan)

^c Kawasaki Clinic   (Japan)

^d Asahi Kasei Medical   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; INTERLEUKIN 6; IRON; PARATHYROID HORMONE; PHOSPHATE; TRANSFERRIN; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BIOCHEMISTRY; CALCIUM BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IRON METABOLISM; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; BLOOD; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM;

AGED; FEMALE; FERRITINS; FIBROBLAST GROWTH FACTORS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 85019043941     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0179139     Document Type: Erratum

References (33)

1. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010; 21:1427-1435 https://doi.org/10.1681/ASN.2009121293 PMID: 20507943
2. GutieÂrrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008 7; 359:584-592 https://doi.org/10.1056/NEJMoa0706130 PMID: 18687639
3. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 15; 305:2432-2439 https://doi.org/10.1001/jama. 2011.826 PMID: 21673295
4. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014; 25:349-360 https://doi.org/10.1681/ASN.2013050465 PMID: 24158986
5. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121:4393-4408 https://doi.org/10.1172/JCI46122 PMID: 21985788
6. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study. J Am Soc Nephrol. 2016; 27:227-237 https://doi.org/10.1681/ASN.2014101009 PMID: 25971439
7. Nowak KL, Bartz TM, Dalrymple L, de Boer IH, Kestenbaum B, Shlipak MG, et al. Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults. J Am Soc Nephrol 2017; 28:1239-1246. https://doi.org/10.1681/ASN.2016040401 PMID: 28122946
8. Mendoza Munoz, Isakova T, Cai X, Bayes, Faul C, Scialla JJ. et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 2017; 91:711-719 https://doi.org/10.1016/j.kint.2016.10.021 PMID: 28017325
9. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014; 289:9795-9810 https://doi.org/10.1074/jbc.M113. 527150 PMID: 24509850
10. Farrow EG, Yu X, Summers LJ, et al: Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. PNAS 2011: 108: E1146-E1155 https://doi.org/10.1073/pnas.1110905108 PMID: 22006328
11. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016; 89:135-146 https://doi.org/10.1038/ki.2015.290 PMID: 26535997
12. Braithwaite V., Jarjou LM., Goldberg GR, Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone. 2012; 50:1351-1356 https://doi.org/10.1016/j.bone.2012.03.010 PMID: 22465847
13. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 2011; 96:3541-3549. https://doi.org/10.1210/jc.2011-1239 PMID: 21880793
14. Bozentowicz-Wikarek M, Kocelak P, Owczarek A, Olszanecka-Glinianowicz M, Mossakowska M, Skalska A, et al. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population? Clin. Biochem. 2015; 48:431-436. https://doi.org/10.1016/j.clinbiochem. 2014.12.027 PMID: 25583093
15. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis. 2015; 65:728-736 https://doi.org/10.1053/j.ajkd.2014.10.014 PMID: 25468387
16. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014; 9:543-552 https://doi.org/10.2215/CJN.05170513 PMID: 24408120
17. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23:1407-1415. https://doi.org/10.1681/ASN. 2012030223 PMID: 22822075
18. Urenã-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H, et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: Results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol. 2014; 15:71 https://doi.org/10.1186/1471-2369-15-71 PMID: 24885942
19. Chang YM, Tsai SC, Shiao CC, Liou HH, Yang CL, Tung NY, et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients. Clin Exp Nephrol. 2017 in press.
20. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011; 33:421-426 https://doi.org/10.1159/000327019 PMID: 21502756
21. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013; 28:1793-1803 https://doi. org/10.1002/jbmr.1923 PMID: 23505057
22. Honda H, Ueda M, Kojima S, Michihata T, Takahashi K, Shishido K, et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis, 2012; 220:493-501 https://doi.org/10.1016/j.atherosclerosis.2011.10.038 PMID: 22119537
23. Kazama JJ: Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Ther Apher Dial. 2007; 11:S44-7 https://doi.org/10.1111/j.1744-9987.2007.00516.x PMID: 17976085
24. Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, et al. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis. PLoS One. 2016; 11:e0151601 https://doi.org/10. 1371/journal.pone.0151601 PMID: 26978524
25. Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, et al. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial. 2004; 8:443-459 https://doi.org/10.1111/j.1774-9987.2004.00199.x PMID: 15663544
26. Roberts MA, Huang L, Lee D, MacGinley R, Troster SM, Kent AB, et al. Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: A randomized controlled trial. BMC Nephrol. 2016; 17:177 https://doi.org/10.1186/s12882-016-0391-7 PMID: 27852236
27. Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, et al. Effects of Dietary Iron Intake and Chronic Kidney Disease on Fibroblast Growth Factor 23 Metabolism in Wild Type and Hepcidin Knockout Mice. Am J Physiol Renal Physiol. 2016; 311:F1369-1377. https://doi.org/10.1152/ajprenal.00281.2016 PMID: 27733366
28. Singh S, Grabner A, Yanucil C, Schramm K1, Czaya B1, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016; 90:985-996 https://doi.org/10.1016/j.kint.2016.05.019 PMID: 27457912
29. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al; Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012; 7:1155-1162 https://doi.org/10.2215/CJN.13281211 PMID: 22554719
30. di Giuseppe R, Kuhn T, Hirche F, Buijsse B, Dierkes J, Fritsche A, et al. Potential predictors of plasma fibroblast growth factor 23 concentrations: Cross-sectional analysis in the EPIC-Germany Study. PLoS One. 2015; 10:e0133580. https://doi.org/10.1371/journal.pone.0133580 PMID: 26193703
31. Hanks LJ, Casazza K, Judd SE, Jenny NS, GutieÂrrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One. 2015; 10:e0122885. https://doi.org/10.1371/journal.pone.0122885 PMID: 25811862
32. Vaziri ND. Safety Issues in Iron Treatment in CKD. Semin Nephrol. 2016; 36:112-118. https://doi.org/10.1016/j.semnephrol.2016.02.005 PMID: 27236132
33. Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol. 2010; 5:576-581 https://doi.org/10.2215/CJN.04710709 PMID: 20110344